Sale

Gemcitabine HCL Market

Global Gemcitabine HCL Market Size, Price, Value, Analysis: By Type: Branded, Generics; By Indications: Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Bladder Cancer, Biliary Tract Cancer, Others; By End User: Hospitals, Homecare, Others; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Gemcitabine HCL Market Outlook

The global Gemcitabine HCl market reached a value of USD 719.26 million in 2023, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 7.4% during the forecast period of 2024-2032 to achieve a value of USD 1,367.49 million by 2032.

 

Global Gemcitabine HCL Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Segmentation

Gemcitabine HCL can be used alone or with a combination of other drugs to treat cancers like breast cancer, non-small cell lung cancer, ovarian cancer, and pancreatic cancer.

 

Global Gemcitabine HCL Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The global gemcitabine HCL market can be segmented based on types, applications, end-uses, and regions.

Based on its types, the industry can be categorised as branded and generic.

Based on its application, the gemcitabine HCL market can be segmented into:

  • Pancreatic Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Non-Small-Cell Lung Carcinoma (NSCLC)
  • Others

Based on its end-uses, the industry can be segmented as hospitals and cancer centres, among others.

The EMR report looks into the regional gemcitabine HCL markets like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Market Analysis

This increase in the number of cancer cases, along with the rising geriatric population and the associated risk factors, is driving the industry for gemcitabine HCL. Further, with the rise in the number of governmental and healthcare patient support organisations and agencies, which are spreading awareness regarding cancer, the industry is expected to receive a further boost. Technical advancements in the production of generic drugs have led to an increase in the demand for gemcitabine HCl, which is expected to propel the global gemcitabine HCl market over the forecast period.

 

Global Gemcitabine HCL Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global gemcitabine HCL market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Eli Lilly and Company (NYSE: LLY)
  • Teva Pharmaceutical Industries Ltd.  
  • Accord Healthcare Ltd. 
  • Pfizer, Inc. 
  • Mylan N.V. 
  • Sun Pharmaceutical Industries Ltd.
  • Fresenius Kabi AG 
  • Dr. Reddy’s Laboratories Ltd. 
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Indications
  • End User
  • Distribution Channel
  • Region
Breakup by Type
  • Branded
  • Generics
Breakup by Indications
  • Breast Cancer
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Biliary Tract Cancer
  • Others
Breakup by End User
  • Hospitals
  • Homecare
  • Specialty Centers
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Fresenius Kabi AG
  • Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
  • Hikma Pharmaceuticals PLC
  • Novartis AG
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd
  • Teva Pharmaceutical Industries Ltd.
  • HEYER Medical AG
  • Biometrix
  • Smith’s Medical
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Gemcitabine HCl Market Overview 

    3.1    Global Gemcitabine HCl Market Historical Value (2017-2023) 
    3.2    Global Gemcitabine HCl Market Forecast Value (2024-2032)
4    Global Gemcitabine HCl Market Landscape
    4.1    Global Gemcitabine HCl Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Gemcitabine HCl Product Landscape
        4.2.1    Analysis by Type
        4.2.2    Analysis by Applications
        4.2.3    Analysis by Classifications
5    Global Gemcitabine HCl Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Gemcitabine HCl Market Segmentation 
    6.1    Global Gemcitabine HCl Market by Type
        6.1.1    Market Overview
        6.1.2    Branded
        6.1.3    Generics
    6.2    Global Gemcitabine HCl Market by Indications
        6.2.1    Market Overview
        6.2.2    Breast Cancer
        6.2.3    Non-Small Cell Lung Cancer
        6.2.4    Ovarian Cancer
        6.2.5    Pancreatic Cancer
        6.2.6    Bladder Cancer
        6.2.7    Biliary Tract Cancer
        6.2.8    Others
    6.3    Global Gemcitabine HCl Market by End User
        6.3.1    Market Overview
        6.3.2    Hospitals
        6.3.3    Homecare
        6.3.4    Specialty Centers
        6.3.5    Others
    6.4    Global Gemcitabine HCl Market by Distribution Channel
        6.4.1    Market Overview
        6.4.2    Hospital Pharmacy
        6.4.3    Online Pharmacy
        6.4.4    Retail Pharmacy
        6.4.5    Others
    6.5    Global Gemcitabine HCl Market by Region
        6.5.1    Market Overview
        6.5.2    North America 
        6.5.3    Europe
        6.5.4    Asia Pacific
        6.5.5    Latin America
        6.5.6    Middle East and Africa
7    North America Gemcitabine HCl Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Gemcitabine HCl Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Gemcitabine HCl Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Gemcitabine HCl Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Gemcitabine HCl Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Pfizer Inc.
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    F. Hoffmann-La Roche Ltd.
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Mylan N.V.
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Fresenius Kabi AG
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Hikma Pharmaceuticals PLC
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Novartis AG
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Shanghai Fosun Pharmaceutical (Group) Co., Ltd
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Teva Pharmaceutical Industries Ltd.
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    HEYER Medical AG
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Biometrix
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Smith’s Medical
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
18    Global Gemcitabine HCl Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global market for gemcitabine HCL reached a value of over USD 719.26 million in 2023.

Over the forecast period of 2024-2032, the market is anticipated to grow at a CAGR of 7.4% to reach USD 1,367.49 million by 2032.

The major drivers of the industry, such as the growing prevalence of cancer and other diseases, rising disposable incomes, increasing population, growing demand for generic drugs, increased government initiatives to create health awareness, growing geriatric population, and rapid advancement in the field of medicine and science, are expected to aid the market growth.

The key market trends guiding the growth of the market include the growing investment in the research and development of drugs and growth in the number of clinical trials being conducted across the globe.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Branded and generic are the major gemcitabine HCL types in the industry.

The significant applications of the product are pancreatic cancer, breast cancer, ovarian cancer, and non-small-cell lung carcinoma (NSCLC), among others.

Hospitals and cancer centres, among others, are the major end use sectors of the product.

The major players in the industry are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Pfizer, Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Fresenius Kabi AG, and Dr. Reddy’s Laboratories Ltd., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER